About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 764213, 15 pages
http://dx.doi.org/10.1155/2012/764213
Review Article

Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme

1Center for Biomaterial Development and Berlin-Brandenburg Center for Regenerative Therapies, Institute of Polymer Research, Helmholtz-Zentrum Geesthacht, 14513 Teltow, Germany
2Department of Neurosurgery, University of Göttingen, 37073 Göttingen, Germany
3Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany

Received 7 November 2011; Accepted 8 December 2011

Academic Editor: Luca Gattinoni

Copyright © 2012 Xun Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Fleury, F. Menegoz, P. Grosclaude, et al., “Descriptive epidemiology of cerebral gliomas in France,” Cancer, vol. 79, no. 6, pp. 1195–1202, 1997.
  2. R. O. Mirimanoff, T. Gorlia, W. Mason et al., “Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial,” Journal of Clinical Oncology, vol. 24, no. 16, pp. 2563–2569, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. W. Stummer, H. J. Reulen, T. Meinel et al., “Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias,” Neurosurgery, vol. 62, no. 3, pp. 564–576, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. W. Stummer, U. Pichlmeier, T. Meinel, O. D. Wiestler, F. Zanella, and H. J. Reulen, “Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial,” The Lancet Oncology, vol. 7, no. 5, pp. 392–401, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. F. Stockhammer, M. Misch, P. Horn, A. Koch, N. Fonyuy, and M. Plotkin, “Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas,” Acta Neurochirurgica, vol. 151, no. 11, pp. 1377–1383, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Westphal, Z. Ram, V. Riddle, D. Hilt, and E. Bortey, “Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial,” Acta Neurochirurgica, vol. 148, no. 3, pp. 269–275, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. P. Menei, P. Metellus, E. Parot-Schinkel et al., “Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience,” Annals of Surgical Oncology, vol. 17, no. 7, pp. 1740–1746, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. W. Kreth, P. C. Warnke, R. Scheremet, and C. B. Ostertag, “Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme,” Journal of Neurosurgery, vol. 78, no. 5, pp. 762–766, 1993. View at Scopus
  9. F. W. Kreth, A. Muacevic, R. Medele, K. Bise, T. Meyer, and H. J. Reulen, “The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours—a prospective study,” Acta Neurochirurgica, vol. 143, no. 6, pp. 539–546, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. E. M. Grasbon-Frodl, F. W. Kreth, M. Ruiter et al., “Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas,” International Journal of Cancer, vol. 121, no. 11, pp. 2458–2464, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. Stupp, M. E. Hegi, W. P. Mason et al., “Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial,” The Lancet Oncology, vol. 10, no. 5, pp. 459–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Hegi, A. C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. P. Hau, D. Koch, T. Hundsberger et al., “Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma,” Neurology, vol. 68, no. 9, pp. 688–690, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. M. V. Barbagallo, M. D. Jenkinson, and A. R. Brodbelt, “'Recurrent' glioblastoma multiforme, when should we reoperate?” British Journal of Neurosurgery, vol. 22, no. 3, pp. 452–455, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. E. S. Mandl, C. M. F. Dirven, D. R. Buis, T. J. Postma, and W. P. Vandertop, “Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy,” Surgical Neurology, vol. 69, no. 5, pp. 506–509, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. E. Combs, M. Bischof, T. Welzel et al., “Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas,” Journal of Neuro-Oncology, vol. 89, no. 2, pp. 205–210, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. T. Villavicencio, S. Burneikiene, P. Romanelli et al., “Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience,” Neurosurgical Review, vol. 32, no. 4, pp. 417–424, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. T. Cloughesy, “FDA accelerated approval benefits glioblastoma,” The Lancet Oncology, vol. 11, no. 12, p. 1120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. J. Vredenburgh, A. Desjardins, J. E. Herndon et al., “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1253–1259, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. J. Vredenburgh, A. Desjardins, J. E. Herndon et al., “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4722–4729, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. H. S. Friedman, M. D. Prados, P. Y. Wen et al., “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4733–4740, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. A. Brandes, A. Tosoni, G. Cavallo et al., “Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO),” British Journal of Cancer, vol. 95, no. 9, pp. 1155–1160, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. Wick, J. Felsberg, J. P. Steinbach et al., “Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3357–3361, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. R. Perry, P. Rizek, R. Cashman, M. Morrison, and T. Morrison, “Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach,” Cancer, vol. 113, no. 8, pp. 2152–2157, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. F. Stockhammer, M. Misch, A. Koch et al., “Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma,” Journal of Neuro-Oncology, vol. 100, no. 3, pp. 407–415, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. Hau, U. Baumgart, K. Pfeifer et al., “Salvage therapy in patients with glioblastoma: is there any benefit?” Cancer, vol. 98, no. 12, pp. 2678–2686, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. Hong and L. Van Kaer, “Immune privilege: keeping an eye on natural killer T cells,” The Journal of Experimental Medicine, vol. 190, no. 9, pp. 1197–1200, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. C. W. Kanaly, D. Ding, A. B. Heimberger, and J. H. Sampson, “Clinical applications of a peptide-based vaccine for glioblastoma,” Neurosurgery Clinics of North America, vol. 21, no. 1, pp. 95–109, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. E. Thara, T. B. Dorff, J. K. Pinski, and D. I. Quinn, “Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer,” Maturitas, vol. 69, no. 4, pp. 296–303, 2011.
  31. S. K. Jacobs, D. J. Wilson, P. L. Kornblith, and E. A. Grimm, “Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial,” Cancer Research, vol. 46, no. 4, pp. 2101–2104, 1986. View at Scopus
  32. R. E. Merchant, A. J. Grant, L. H. Merchant, and H. F. Young, “Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2,” Cancer, vol. 62, no. 4, pp. 665–671, 1988. View at Scopus
  33. D. Barba, S. C. Saris, C. Holder, S. A. Rosenberg, and E. H. Oldfield, “Intratumoral LAK cell and interleukin-2 therapy of human gliomas,” Journal of Neurosurgery, vol. 70, no. 2, pp. 175–182, 1989. View at Scopus
  34. K. O. Lillehei, D. H. Mitchell, S. D. Johnson, E. L. McCleary, and C. A. Kruse, “Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy,” Neurosurgery, vol. 28, no. 1, pp. 16–23, 1991. View at Scopus
  35. E. W. B. Jeffes III, Y. B. Beamer, S. Jacques et al., “Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA,” Journal of Neuro-Oncology, vol. 15, no. 2, pp. 141–155, 1993. View at Scopus
  36. A. Blancher, F. Roubinet, A. S. Grancher et al., “Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells,” European Cytokine Network, vol. 4, no. 5, pp. 331–341, 1993. View at Scopus
  37. A. Boiardi, A. Silvani, P. Adelchi Ruffini et al., “Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients,” Cancer Immunology Immunotherapy, vol. 39, no. 3, pp. 193–197, 1994. View at Scopus
  38. R. L. Hayes, M. Koslow, E. M. Hiesiger et al., “Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma,” Cancer, vol. 76, no. 5, pp. 840–852, 1995. View at Publisher · View at Google Scholar
  39. S. K. Sankhla, J. S. Nadkarni, and S. N. Bhagwati, “Adoptive immimotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrentmalignant primary brain tumors,” Journal of Neuro-Oncology, vol. 27, no. 2, pp. 133–140, 1995.
  40. R. L. Hayes, E. Arbit, M. Odaimi et al., “Adoptive cellular immunotherapy for the treatment of malignant gliomas,” Critical Reviews in Oncology/Hematology, vol. 39, no. 1-2, pp. 31–42, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. R. O. Dillman, C. M. Duma, P. M. Schiltz et al., “Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma,” Journal of Immunotherapy, vol. 27, no. 5, pp. 398–404, 2004. View at Scopus
  42. R. O. Dillman, C. M. Duma, R. A. Ellis et al., “Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma,” Journal of Immunotherapy, vol. 32, no. 9, pp. 914–919, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. F. P. Holladay, “Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/IV astrocytoma,” Journal of Neuro-Oncology, vol. 27, no. 2, pp. 179–189, 1996. View at Scopus
  44. G. E. Plautz, G. H. Barnett, D. W. Miller et al., “Systemic T cell adoptive immunotherapy of malignant gliomas,” Journal of Neurosurgery, vol. 89, no. 1, pp. 42–51, 1998. View at Scopus
  45. G. E. Plautz, D. W. Miller, G. H. Barnett et al., “T cell adoptive immunotherapy of newly diagnosed gliomas,” Clinical Cancer Research, vol. 6, no. 6, pp. 2209–2218, 2000. View at Scopus
  46. G. W. Wood, F. P. Holladay, T. Turner, Y. Y. Wang, and M. Chiga, “A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma,” Journal of Neuro-Oncology, vol. 48, no. 2, pp. 113–120, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. A. E. Sloan, R. Dansey, L. Zamorano et al., “Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes,” Neurosurgical Focus, vol. 9, no. 6, p. e9, 2000. View at Scopus
  48. C. A. Kruse, L. Cepeda, B. Owens, S. D. Johnson, J. Stears, and K. O. Lillehei, “Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2,” Cancer Immunology Immunotherapy, vol. 45, no. 2, pp. 77–87, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. K. B. Quattrocchi, C. H. Miller, S. Cush et al., “Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas,” Journal of Neuro-Oncology, vol. 45, no. 2, pp. 141–157, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Kronik, Y. Kogan, V. Vainstein, and Z. Agur, “Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics,” Cancer Immunology, Immunotherapy, vol. 57, no. 3, pp. 425–439, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. R. E. Sobol, H. Fakhrai, D. Shawler et al., “Interleukin-2 gene therapy in a patient with glioblastoma,” Gene Therapy, vol. 2, no. 2, pp. 164–167, 1995. View at Scopus
  52. T. Schneider, R. Gerhards, E. Kirches, and R. Firsching, “Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme,” Journal of Neuro-Oncology, vol. 53, no. 1, pp. 39–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. D. W. Andrews, M. Resnicoff, A. E. Flanders et al., “Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas,” Journal of Clinical Oncology, vol. 19, no. 8, pp. 2189–2200, 2001. View at Scopus
  54. H. Okada, F. S. Lieberman, H. D. Edington et al., “Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,” Journal of Neuro-Oncology, vol. 64, no. 1-2, pp. 13–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. H. H. Steiner, M. M. Bonsanto, P. Beckhove et al., “Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefits,” Journal of Clinical Oncology, vol. 22, no. 21, pp. 4272–4281, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. I. F. Parney, L. J. Chang, M. A. Farr-Jones, C. Hao, M. Smylie, and K. C. Petruk, “Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas,” Journal of Neuro-Oncology, vol. 78, no. 1, pp. 71–80, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. E. Ishikawa, K. Tsuboi, T. Yamamoto et al., “Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients,” Cancer Science, vol. 98, no. 8, pp. 1226–1233, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. Clavreul, N. Piard, J. Y. Tanguy et al., “Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas,” Journal of Clinical Neuroscience, vol. 17, no. 7, pp. 842–848, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of dendritic cells,” Annual Review of Immunology, vol. 18, pp. 767–811, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. R. M. Steinman and J. Banchereau, “Taking dendritic cells into medicine,” Nature, vol. 449, no. 7161, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. H. Okada, P. Kalinski, R. Ueda, et al., “Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma,” Journal of Clinical Oncology, vol. 29, no. 3, pp. 330–336, 2011.
  62. R. M. Prins, H. Soto, V. Konkankit et al., “Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy,” Clinical Cancer Research, vol. 17, no. 6, pp. 1603–1615, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. H. Ardon, S. Van Gool, I. S. Lopes et al., “Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study,” Journal of Neuro-Oncology, vol. 99, no. 2, pp. 261–272, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. H. Ardon, S. De Vleeschouwer, F. Van Calenbergh et al., “Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours,” Pediatric Blood and Cancer, vol. 54, no. 4, pp. 519–525, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. J. H. Sampson, G. E. Archer, D. A. Mitchell et al., “An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme,” Molecular Cancer Therapeutics, vol. 8, no. 10, pp. 2773–2779, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. S. De Vleeschouwer, S. Fieuws, S. Rutkowski et al., “Postoperative adjuvant dendritic cell—based immunotherapy in patients with relapsed glioblastoma multiforme,” Clinical Cancer Research, vol. 14, no. 10, pp. 3098–3104, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. C. J. Wheeler, K. L. Black, G. Liu et al., “Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients,” Cancer Research, vol. 68, no. 14, pp. 5955–5964, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. R. Yamanaka, J. Homma, N. Yajima et al., “Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial,” Clinical Cancer Research, vol. 11, no. 11, pp. 4160–4167, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. L. M. Liau, R. M. Prins, S. M. Kiertscher et al., “Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment,” Clinical Cancer Research, vol. 11, no. 15, pp. 5515–5525, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. J. S. Yu, G. Liu, H. Ying, W. H. Yong, K. L. Black, and C. J. Wheeler, “Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma,” Cancer Research, vol. 64, no. 14, pp. 4973–4979, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. T. Kikuchi, Y. Akasaki, T. Abe et al., “Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12,” Journal of Immunotherapy, vol. 27, no. 6, pp. 452–459, 2004. View at Scopus
  72. D. A. Caruso, L. M. Orme, A. M. Neale et al., “Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer,” Neuro-Oncology, vol. 6, no. 3, pp. 236–246, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. C. J. Wheeler, A. Das, G. Liu, J. S. Yu, and K. L. Black, “Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination,” Clinical Cancer Research, vol. 10, no. 16, pp. 5316–5326, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. R. Yamanaka, T. Abe, N. Yajima et al., “Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial,” British Journal of Cancer, vol. 89, no. 7, pp. 1172–1179, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. J. S. Yu, C. J. Wheeler, P. M. Zeltzer et al., “Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration,” Cancer Research, vol. 61, no. 3, pp. 842–847, 2001. View at Scopus
  76. C. J. Wheeler, K. L. Black, G. Liu, et al., “Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality,” The Journal of Immunology, vol. 171, no. 9, pp. 4927–4933, 2003.
  77. S. Tuyaerts, J. L. Aerts, J. Corthals et al., “Current approaches in dendritic cell generation and future implications for cancer immunotherapy,” Cancer Immunology, Immunotherapy, vol. 56, no. 10, pp. 1513–1537, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. H. Okada, F. S. Lieberman, K. A. Walter et al., “Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas,” Journal of Translational Medicine, vol. 5, article 67, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. M. Kogiku, I. Ohsawa, K. Matsumoto et al., “Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor,” Journal of Clinical Neuroscience, vol. 15, no. 11, pp. 1198–1203, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. S. A. Rosenberg, “Cancer vaccines based on the identification of genes encoding cancer regression antigens,” Immunology Today, vol. 18, no. 4, pp. 175–182, 1997. View at Publisher · View at Google Scholar · View at Scopus
  81. R. F. Wang, “The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity,” Trends in Immunology, vol. 22, no. 5, pp. 269–276, 2001.
  82. N. C. Fernandez, A. Lozier, C. Flament et al., “Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo,” Nature Medicine, vol. 5, no. 4, pp. 405–411, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. R. Wehner, B. Löbel, M. Bornhäuser et al., “Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cell,” International Journal of Cancer, vol. 124, no. 2, pp. 358–366, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. M. Schmitz, S. Zhao, Y. Deuse et al., “Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity,” The Journal of Immunology, vol. 174, no. 7, pp. 4127–4134, 2005. View at Scopus
  85. C. E. Fadul, J. L. Fisher, T. H. Hampton et al., “Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy,” Journal of Immunotherapy, vol. 34, no. 4, pp. 382–389, 2011. View at Publisher · View at Google Scholar · View at PubMed
  86. M. Hatano, J. Eguchi, T. Tatsumi et al., “EphA2 as a glioma-associated antigen: a novel target for glioma vaccines,” Neoplasia, vol. 7, no. 8, pp. 717–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Schmitz, R. Wehner, S. Stevanovic et al., “Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11,” Cancer Letters, vol. 245, no. 1-2, pp. 331–336, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu, “HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,” Cancer Research, vol. 64, no. 14, pp. 4980–4986, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. S. Saikali, T. Avril, B. Collet et al., “Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy,” Journal of Neuro-Oncology, vol. 81, no. 2, pp. 139–148, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. H. Okada, G. Kohanbash, X. Zhu et al., “Immunotherapeutic approaches for glioma,” Critical Reviews in Immunology, vol. 29, no. 1, pp. 1–42, 2009. View at Scopus
  91. R. Ueda, K. L. Low, X. Zhu et al., “Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma,” Journal of Translational Medicine, vol. 5, article 68, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. J. G. Zhang, C. A. Kruse, L. Driggers et al., “Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy,” Journal of Neuro-Oncology, vol. 88, no. 1, pp. 65–76, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. D. L. Scarcella, C. W. Chow, M. F. Gonzales, C. Economou, F. Brasseur, and D. M. Ashley, “Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers,” Clinical Cancer Research, vol. 5, no. 2, pp. 335–341, 1999. View at Scopus
  94. L. Bao, K. Dunham, and K. Lucas, “MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing,” Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1299–1307, 2011. View at Publisher · View at Google Scholar · View at PubMed
  95. G. Z. Jian, J. Eguchi, C. A. Kruse et al., “Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics,” Clinical Cancer Research, vol. 13, no. 2, pp. 566–575, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. G. Liu, J. S. Yu, G. Zeng et al., “AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,” Journal of Immunotherapy, vol. 27, no. 3, pp. 220–226, 2004. View at Scopus
  97. L. Driggers, J. G. Zhang, E. W. Newcomb, L. Ge, N. Hoa, and M. R. Jadus, “Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper,” Journal of Neuro-Oncology, vol. 97, no. 2, pp. 159–169, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. Q. Xu, G. Liu, X. Yuan et al., “Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens,” Stem Cells, vol. 27, no. 8, pp. 1734–1740, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. M. Abdouh, S. Facchino, W. Chatoo, V. Balasingam, J. Ferreira, and G. Bernier, “BMI1 sustains human glioblastoma multiforme stem cell renewal,” The Journal of Neuroscience, vol. 29, no. 28, pp. 8884–8896, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang, “Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations,” Cancer Research, vol. 61, no. 11, pp. 4375–4381, 2001. View at Scopus
  101. F. Orzan, S. Pellegatta, P. L. Poliani et al., “Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells,” Neuropathology and Applied Neurobiology, vol. 37, no. 4, pp. 381–394, 2011. View at Publisher · View at Google Scholar · View at PubMed
  102. L. Cheng, Q. Wu, O. A. Guryanova et al., “Elevated invasive potential of glioblastoma stem cells,” Biochemical and Biophysical Research Communications, vol. 406, no. 4, pp. 643–648, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. F. Jin, L. Zhao, Y. J. Guo et al., “Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells,” Brain Research, vol. 1336, pp. 103–111, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. C. T. Kuan, K. Wakiya, J. E. Herndon et al., “MRP3: a molecular target for human glioblastoma multiforme immunotherapy,” BMC Cancer, vol. 10, article 468, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. T. Ishiwata, K. Teduka, T. Yamamoto, K. Kawahara, Y. Matsuda, and Z. Naito, “Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas,” Oncology Reports, vol. 26, no. 1, pp. 91–99, 2011. View at Publisher · View at Google Scholar · View at PubMed
  106. K. L. Ligon, J. A. Alberta, A. T. Kho et al., “The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 5, pp. 499–509, 2004. View at Scopus
  107. L. Annovazzi, M. Mellai, V. Caldera, G. Valente, and D. Schiffer, “SOX2 expression and amplification in gliomas and glioma cell lines,” Cancer Genomics and Proteomics, vol. 8, no. 3, pp. 139–147, 2011.
  108. S. Kakino, K. Sasaki, A. Kurose, and H. Ito, “Intracellular localization of cyclin B1 during the cell cycle in glioma cells,” Cytometry, vol. 24, no. 1, pp. 49–54, 1996. View at Publisher · View at Google Scholar
  109. M. Rossi, L. Magnoni, C. Miracco et al., “β-catenin and Gli1 are prognostic markers in glioblastoma,” Cancer Biology and Therapy, vol. 11, no. 8, pp. 753–761, 2011. View at Publisher · View at Google Scholar
  110. D. Cui, Q. Xu, K. Wang, and X. Che, “Gli1 is a potential target for alleviating multidrug resistance of gliomas,” Journal of the Neurological Sciences, vol. 288, no. 1-2, pp. 156–166, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. R. Senetta, C. Miracco, S. Lanzafame et al., “Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes,” Neuro-Oncology, vol. 13, no. 2, pp. 176–183, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. M. Sivaparvathi, R. Sawaya, S. W. Wang et al., “Overexpression and localization of cathepsin B during the progression of human gliomas,” Clinical and Experimental Metastasis, vol. 13, no. 1, pp. 49–56, 1995. View at Publisher · View at Google Scholar · View at Scopus
  113. G. J. Kitange, B. L. Carlson, M. A. Schroeder, et al., “Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance,” Journal of Neuro-Oncology, vol. 100, no. 2, pp. 177–186, 2010.
  114. L. J. Lewis-Tuffin, F. Rodriguez, C. Giannini et al., “Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype,” PLoS ONE, vol. 5, no. 10, Article ID e13665, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski, “EphA2 as a novel molecular marker and target in glioblastoma multiforme,” Molecular Cancer Research, vol. 3, no. 10, pp. 541–551, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski, “Interleukin-13 receptor α2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy,” Clinical Cancer Research, vol. 14, no. 1, pp. 199–208, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. H. D. Mennel and B. Lell, “Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors,” Clinical Neuropathology, vol. 24, no. 1, pp. 13–18, 2005.
  118. H. Yamamoto, J. Swoger, S. Greene et al., “β1,6-N-acethylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity,” Cancer Research, vol. 60, no. 1, pp. 134–142, 2000. View at Scopus
  119. O. Persson, L. G. Salford, J. Fransson, B. Widegren, C. A. K. Borrebaeck, and B. Holmqvist, “Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme,” Journal of Neuro-Oncology, vol. 97, no. 2, pp. 207–215, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. T. Elsir, A. Eriksson, A. Orrego, M. S. Lindström, and M. Nistér, “Expression of PROX1 is a common feature of high-grade malignant astrocytic gliomas,” Journal of Neuropathology and Experimental Neurology, vol. 69, no. 2, pp. 129–138, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. K. D. Geiger, S. Hendruschk, E. P. Rieber et al., “The prostate stem cell antigen represents a novel glioma-associated antigen,” Oncology Reports, vol. 26, no. 1, pp. 13–21, 2011. View at Publisher · View at Google Scholar · View at PubMed
  122. M. Ferletta, L. Uhrbom, T. Olofsson, F. Pontén, and B. Westermark, “Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B—induced gliomagenesis,” Molecular Cancer Research, vol. 5, no. 9, pp. 891–897, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. C. S. Gondi, S. S. Lakka, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao, “RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas,” Oncogene, vol. 23, no. 52, pp. 8486–8496, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. G. G. Gomez and C. A. Kruse, “Mechanisms of malignant glioma immune resistance and sources of immunosuppression,” Gene Therapy and Molecular Biology, vol. 10, no. 1, pp. 133–146, 2006. View at Scopus
  125. C. S. Cobbs, L. Harkins, M. Samanta et al., “Human cytomegalovirus infection and expression in human malignant glioma,” Cancer Research, vol. 62, no. 12, pp. 3347–3350, 2002. View at Scopus
  126. R. M. Prins, T. F. Cloughesy, and L. M. Liau, “Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate,” New England Journal of Medicine, vol. 359, no. 5, pp. 539–541, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. D. A. Mitchell, W. Xie, R. Schmittling et al., “Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma,” Neuro-Oncology, vol. 10, no. 1, pp. 10–18, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. L. Bao, K. Dunham, M. Stamer, K. M. Mulieri, and K. G. Lucas, “Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 14, no. 10, pp. 1156–1162, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. L. Bao, Q. Sun, and K. G. Lucas, “Rapid generation of CMV pp65-specific T cells for immunotherapy,” Journal of Immunotherapy, vol. 30, no. 5, pp. 557–561, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. J. Yao, C. Bechter, M. Wiesneth et al., “Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study,” Clinical Infectious Diseases, vol. 46, no. 10, pp. e96–e105, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. A. Schmitt, T. Tonn, D. H. Busch et al., “Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation,” Transfusion, vol. 51, no. 3, pp. 591–599, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. J. D. Fontenot, J. P. Rasmussen, M. A. Gavin, and A. Y. Rudensky, “A function for interleukin 2 in Foxp3-expressing regulatory T cells,” Nature Immunology, vol. 6, no. 11, pp. 1142–1151, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. A. El Andaloussi and M. S. Lesniak, “An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme,” Neuro-Oncology, vol. 8, no. 3, pp. 234–243, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. P. E. Fecci, D. A. Mitchell, J. F. Whitesides et al., “Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma,” Cancer Research, vol. 66, no. 6, pp. 3294–3302, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz et al., “Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas,” Clinical Cancer Research, vol. 14, no. 16, pp. 5166–5172, 2008. View at Publisher · View at Google Scholar · View at PubMed
  136. F. Annunziato, L. Cosmi, F. Liotta, E. Maggi, and S. Romagnani, “The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation,” International Immunology, vol. 20, no. 11, pp. 1361–1368, 2008.
  137. Y. Y. Wan and R. A. Flave I I, “How diverse—CD4 effector T cells and their functions,” Journal of Molecular Cell Biology, vol. 1, no. 1, pp. 20–36, 2009.
  138. P. Muranski, A. Boni, P. A. Antony et al., “Tumor-specific Th17-polarized cells eradicate large established melanoma,” Blood, vol. 112, no. 2, pp. 362–373, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  139. D. A. Wainwright, S. Sengupta, Y. Han, I. V. Ulasov, and M. S. Lesniak, “The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human gliom,” PLoS ONE, vol. 5, no. 10, Article ID e15390, 2010. View at Publisher · View at Google Scholar · View at PubMed
  140. J. C. Rodrigues, G. C. Gonzalez, L. Zhang et al., “Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties,” Neuro-Oncology, vol. 12, no. 4, pp. 351–365, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. B. Raychaudhuri, P. Rayman, J. Ireland, et al., “Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma,” Neuro-Oncology, vol. 13, no. 6, pp. 591–599, 2011. View at Publisher · View at Google Scholar · View at PubMed
  142. H. Ghebeh, M. M. Bakr, and S. Dermime, “Cancer stem cell immunotherapy: the right bullet for the right target,” Hematology/Oncology and Stem Cell Therapy, vol. 1, no. 1, pp. 1–2, 2008. View at Scopus
  143. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. G. Liu, X. Yuan, Z. Zeng et al., “Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,” Molecular Cancer, vol. 5, article 67, 2006. View at Publisher · View at Google Scholar · View at PubMed
  145. S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Research, vol. 63, no. 18, pp. 5821–5828, 2003. View at Scopus
  146. L. Prestegarden, A. Svendsen, J. Wang et al., “Glioma cell populations grouped by different cell type markers drive brain tumor growth,” Cancer Research, vol. 70, no. 11, pp. 4274–4279, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  147. S. Pellegatta, P. L. Poliani, D. Corno et al., “Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,” Cancer Research, vol. 66, no. 21, pp. 10247–10252, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. R. Wang, K. Chadalavada, J. Wilshire et al., “Glioblastoma stem-like cells give rise to tumour endothelium,” Nature, vol. 468, no. 7325, pp. 829–835, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  149. L. Ricci-Vitiani, R. Pallini, M. Biffoni et al., “Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells,” Nature, vol. 468, no. 7325, pp. 824–830, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. R. A. Lake and B. W. S. Robinson, “Immunotherapy and chemotherapy—apractical partnership,” Nature Reviews Cancer, vol. 5, no. 5, pp. 397–405, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  151. C. Bourquin, S. Schreiber, S. Beck, G. Hartmann, and S. Endres, “Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer,” International Journal of Cancer, vol. 118, no. 11, pp. 2790–2795, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. C. H. Kim, S. J. Woo, J. S. Park et al., “Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma,” Immunology, vol. 122, no. 4, pp. 615–622, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  153. X. Xu, F. Stockhammer, A. Schmitt, et al., “Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells,” International Journal of Oncology, vol. 40, no. 3, pp. 764–772.